tetano
Editor, Senior Moderator
Rinsho Ketsueki
. 2021;62(11):1639-1642.
doi: 10.11406/rinketsu.62.1639.
[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination]
[Article in Japanese]
Ayako Matsumura[SUP] 1 [/SUP], Kengo Katsuki[SUP] 1 [/SUP], Masahiro Akimoto[SUP] 1 [/SUP], Takayuki Sakuma[SUP] 1 [/SUP], Yuki Nakajima[SUP] 1 [/SUP], Takuya Miyazaki[SUP] 1 [/SUP], Shin Fujisawa[SUP] 1 [/SUP], Hideaki Nakajima[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic until today, but treatment options remain limited. COVID-19 vaccination is expected to decrease the number of patients with COVID-19 worldwide. In Japan, two types of mRNA COVID-19 vaccine, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have been approved and administered. However, their side effects remain poorly elucidated. This paper presents two cases of immune thrombocytopenia (ITP) after BNT162b2 mRNA COVID-19 vaccination. Whether or not ITP is triggered by the vaccination or not is difficult to identify. Further investigation with a large number of cases is warranted to clarify the side effects of BNT162b2 mRNA COVID-19 vaccination.
Keywords: COVID-19; Immune thrombocytopenia; SARS-CoV-2 vaccine.
. 2021;62(11):1639-1642.
doi: 10.11406/rinketsu.62.1639.
[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination]
[Article in Japanese]
Ayako Matsumura[SUP] 1 [/SUP], Kengo Katsuki[SUP] 1 [/SUP], Masahiro Akimoto[SUP] 1 [/SUP], Takayuki Sakuma[SUP] 1 [/SUP], Yuki Nakajima[SUP] 1 [/SUP], Takuya Miyazaki[SUP] 1 [/SUP], Shin Fujisawa[SUP] 1 [/SUP], Hideaki Nakajima[SUP] 2 [/SUP]
Affiliations
- PMID: 34866090
- DOI: 10.11406/rinketsu.62.1639
Abstract
Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic until today, but treatment options remain limited. COVID-19 vaccination is expected to decrease the number of patients with COVID-19 worldwide. In Japan, two types of mRNA COVID-19 vaccine, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have been approved and administered. However, their side effects remain poorly elucidated. This paper presents two cases of immune thrombocytopenia (ITP) after BNT162b2 mRNA COVID-19 vaccination. Whether or not ITP is triggered by the vaccination or not is difficult to identify. Further investigation with a large number of cases is warranted to clarify the side effects of BNT162b2 mRNA COVID-19 vaccination.
Keywords: COVID-19; Immune thrombocytopenia; SARS-CoV-2 vaccine.